Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04512781 · ClinicalTrials.gov registry record · NA

Clinical Efficacy in Relief of Dyspnea by HVNI: Evaluation of New Cannulae Designs

A NA study of Dyspnea and Respiratory Insufficiency, sponsored by Vapotherm.

Completed
Registry status
NA
Development phase
26
Enrollment target
2
Study locations

NCT04512781 is a NA study of Dyspnea and Respiratory Insufficiency that has completed, run by Vapotherm. The registered enrollment target is 26 participants, below the 304-participant average among 23 other Dyspnea trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04512781, a NA study of Dyspnea and Respiratory Insufficiency, has completed, sponsored by Vapotherm.

COMPLETED
Registry status
NA
Development phase
26 participants
Enrollment target
2
Study locations

Study Summary

This study will evaluate the ability of High Velocity Nasal Insufflation \[HVNI\] next generation nasal cannula designs to effect ventilation and related physiological responses relative to the conventional legacy cannula design.

Interventions

  • DEVICE Control Cannula - Prosoft Cannula - Unicorn Cannula
  • DEVICE Control Cannula - Unicorn Cannula - Prosoft Cannula

Study Locations (2)

Pennsylvania

  • VA Pittsburgh Healthcare System - Pittsburgh

Tennessee

  • Erlanger Baroness Hospital - Chattanooga

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2020-10-01
Est. Completion 2022-06-07
Phase NA

Sponsor

Vapotherm

7 total trials

What the Registry Record Tells You About NCT04512781

The ClinicalTrials.gov registry entry for NCT04512781 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 304-participant average among 23 other Dyspnea trials with a reported enrollment target (91% lower). The listed sponsor is Vapotherm, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Dyspnea appearing as the primary indexed condition, and to 2 interventions - of which Control Cannula - Prosoft Cannula - Unicorn Cannula is the first listed.

NCT04512781 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Pennsylvania, Tennessee.

Frequently Asked Questions

What is clinical trial NCT04512781 about?

NCT04512781 is a clinical study titled "Clinical Efficacy in Relief of Dyspnea by HVNI: Evaluation of New Cannulae Designs". This study will evaluate the ability of High Velocity Nasal Insufflation \[HVNI\] next generation nasal cannula designs to effect ventilation and related physiological responses relative to the conventional legacy cannula design.

What is the current status of trial NCT04512781?

This trial is currently completed. It is a NA study. The enrollment target is 26 participants. The study started on 2020-10-01. Estimated completion is 2022-06-07.

What conditions does trial NCT04512781 study?

This clinical trial studies the following conditions: Dyspnea, Respiratory Insufficiency, Hypercapnia.

What interventions are being tested in trial NCT04512781?

The interventions under investigation include: Control Cannula - Prosoft Cannula - Unicorn Cannula (DEVICE), Control Cannula - Unicorn Cannula - Prosoft Cannula (DEVICE).

Who is sponsoring clinical trial NCT04512781?

This trial is sponsored by Vapotherm, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04512781 being conducted?

This trial has 2 study locations across Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Dyspnea

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.